AstraZeneca PLC (AZN) Earnings Call Transcripts
AstraZeneca PLC's Latest Earnings Call - Q1 FY2026
In Q1 2026, AstraZeneca (AZN:GB) reported total revenue of $12.6 billion, reflecting an 8% year-over-year increase, driven by strong demand for innovative medicines, particularly in oncology and rare diseases. Core EPS grew 5% to $2.58, slightly below expectations due to a low tax rate in the prior year. Management maintained full-year guidance, expecting total revenue growth in the mid- to high single-digit range and core EPS growth in the low double-digit percentage range, signaling confidence in ongoing product launches and pipeline advancements.
Reported metrics
| Metric | Value |
|---|---|
| Total Revenue | $12.6B (beat) |
| Core EPS | $2.58 (miss) |
| Oncology Revenue | $6.8B (positive) |
| Biopharmaceuticals Revenue | $5.8B (negative) |
| Core R&D Expenses | 23% of total revenue (neutral) |
| Cash Flow from Operations | $3.4B (neutral) |
Guidance from management
Management maintained full-year guidance, expecting total revenue to increase by mid- to high single-digit percentages and core EPS to increase by low double-digit percentages at constant exchange rates.
What management said
As Joris mentioned at the start of the call, and we will see if he's more successful than his predecessor R&D. Please limit the number of questions you ask to allow others a fair chance to participate. [Operator Instructions] And now let's move to the first question, which is from Richard Vosser at JPMorgan.
Yes. And the only thing, Richard, I would like to add regarding the potential is that the current biologics in COPD are primarily for high use in the fields. These studies were done above 300 million I think the uniqueness as Sharon has shared is that this is across the eosinophil account of patients -- so whether in the end of the day, physicians want to test in COPD, the infill count is up to them, but we are hopin...
What analysts pressed on
Analysts expressed concerns regarding the decline in biopharmaceutical revenues and the impact of loss of exclusivity on key products like Farxiga. There were also questions about the competitive landscape for new product launches and the sustainability of growth in emerging markets.
Main topics on the call
- Strong Revenue Growth — Total revenue increased by 8% to $12.6 billion, supported by robust demand for innovative medicines. Management noted, "We delivered a strong first quarter, building on the momentum we generated in 2025."
- Oncology Performance — Oncology revenues grew 16% to $6.8 billion, with double-digit growth across all geographic segments. Management highlighted that "Tagrisso remains the treatment of choice with an increasing proportion of physicians optin...
- Pipeline Advancements — Management announced the successful results of four Phase III programs, including tozorakimab and efzimfotase alfa, indicating ongoing investment in R&D. They stated, "We are well placed to grow through 2030 and beyond."
- Challenges in Biopharmaceuticals — Total revenue for biopharmaceuticals declined by 2% to $5.8 billion, primarily due to anticipated headwinds from Brilinta and Farxiga. Management noted, "2026 marks a transition year for CVM as we navigate loss of exclus...
Read the full AstraZeneca PLC transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About AstraZeneca PLC
AstraZeneca PLC (AZN) is a publicly listed company in the Pharmaceuticals industry, within the Health Care sector. It trades on LSE and is based in GB. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 60 calls on record spanning February 14, 2020 to July 27, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 60 AstraZeneca PLC earnings call transcripts on record, spanning February 14, 2020 to July 27, 2026. Based on this history, AstraZeneca PLC reports quarterly. The most recent call on file is dated July 27, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- AZN
- Exchange
- LSE
- Country
- GB
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Calls on record
- 60
- First call
- February 14, 2020
- Most recent
- July 27, 2026
- Reporting cadence
- quarterly